Pharmaceutical blockade of the neonatal Fc receptor (FcRn) ameliorates autoimmunity, inflammation, and fibrosis in the antitopoisomerase-I antibody–driven mouse model of systemic sclerosis

Annals of the Rheumatic Diseases · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles